POSSIBILITIES OF THERAPY OF HER-2-POSITIVE REGIONAL BREAST CANCER

Breast cancer heads the list of malignant neoplasms in women. In this connection the regional forms of cancer are diagnosed in one fourth of the patients. The treatment of regional cancer begins with systemic therapy and aimed at gaining of state fit for operation. The choice of modern treatment strategy is based on determination of molecular subtype of the tumor. One of them is referred to HER-2-positive cancer, requiring the administration of additional targeted therapy. This form of cancer is referred to prognostically pejorative tumors, as it’s more aggressive, leads to fast metastasis and early death of the patients. The “golden standard” of systemic chemotherapy is defined as administration of docetaxel and trastuzumab,  and antracyclic drugs, which also prove to be efficient. However concomitant administration of trastuzumab and antracyclines is limited due to their cardiotoxicity. Chemotherapy is not always efficient and, upon recommendations both of Russian and international oncologists, radiotherapy is the next stage of treatment. The question about radiosensibility of HER-2-positive tumors is still open and worth studying. Addition of radiotherapy to regional cancer treatment regimen in combination with the targeted therapy and chemotherapy may contribute to obtaining better survival rate and disease control. There are still no clearly defined standard for the sequence of chemo-radiation therapy. Simultaneous  chemo-radiatiojn  therapy results in  reliably better loco-regional control of tumor and  enables to gain a  higher degree of pathomorphological response on the one hand, and it may result in development of serious adverse effects on the other hand. Striving for improvement of immediate results of antineoplastic therapy, including that of regional cancer, by combining various methods, one should keep in mind the increasing action toxicity, which may have a considerable impact on the patients’ quality of living. Continuation of experiments and clinical trials in this direction is rather actual, as it allows getting new data for treatment of regional breast cancer.

1. Состояние онкологической помощи на- селению России в 2013 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2014. С. 18–26. [Status of cancer care for the people of Russia in 2013. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Pet- rova. Moscow, 2014. Pp. 18–26. (In Russ.)].

2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. СA Cancer J Clin 2014;64(1): 9–29.

3. Hortobagyi G.N., Singletary S.E., Buchholz T.A. Locally advanced breast cancer. In: Advanced therapy of breast disease. 2nd ed. London, 2004. Pр. 498–508.

4. Беришвили А.И. Отечно-инфильтратив- ная форма рака молочной железы (клини- ка, диагностика, лечение, факторы прогноза). Автореф. дис. … д-ра мед. наук. М., 2011. [Berishvili A.I. Inflammatory breast carcinoma (clinical picture, diagnostics, treatment, prognosis factors). Author's abstract of thesis ... of doctor of medical sciences Moscow, 2011. (In Russ.)].

5. Anderson W.F., Chu K.C., Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 2003;21(12):2254–9.

6. Kim H.A., Kim E.K., Kim M.S. et al. Association of human epidermal growth factor receptor 2 with radiotherapy resistance in patients with T1N0M0 breast cancer. J Breast Cancer 2013;16(3):266–73.

7. Saracchini S., Foltran L., Tuccia F. et al. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast 2013;22(6):1101–7.

8. Семиглазов В.Ф., Манихас А.Г., Божок А.А. и др. Неоадъювантная терапия рака молочной железы с повышенной экс- прессией HER-2. Фарматека 2010;14(208): 12–7. [Semiglazov V.F., Manikhas А.G., Bozhok А.А. et al. Neoajuvant therapy of breast cancer with HER-2 overexpression. Farmateka = Farmateka 2010;14(208):12–7. (In Russ.)].

9. Botrel T.E., Paladini L., Clark O.A. Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis. Core Evidence 2013;8:69–78.

10. Kaufman B., Mackey J.R., Clemens M.R. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27(33):5529–37.

11. Харченко В.П., Рожкова Н.И. Маммо- логия: национальное руководство. М., 2009. С. 251–3. [Kharchenko V.P., Rozhkova N.I. Breast Care: National Guide. Moscow, 2009. Pp. 251–3. (In Russ.)].

12. Formenti S.C., Dunnington G., Uzieli B. et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluor ouracil and radiation therapy. Int J Radiat Oncol Biol Phys 1997;39(5):1059–68.

13. Hickey B.E., Francis D.P., Lehman M. Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev 2013;4:CD005212.

14. Ткачев С.И., Михина З.П., Трофимова О.П. и др. Лучевая терапия рака молочной железы. Доклад Заседания Мос- ковского онкологического общества. М., 2008. [Tkachev S.I., Mikhina Z.P., Trofimova O.P. et al. Breast cancer radiotherapy. Report of meeting of the Moscow Cancer Society. Moscow, 2008. (In Russ.)].

15. Болотина Л.В., Закиряходжаев А.Д., Малыгин С.Е. и др. Клинические рекомен- дации по профилактике, диагностике и лечению больных раком молочной железы. М., 2014. С. 31–2. [Bolotina L.V., Zakiryakhodzhaev A.D., Malygin S.E. et al. Clinical recommendations for prevention, diagnostics and treatment of breast cancer patients. Moscow, 2014. Pp. 31–2. (In Russ.)].

16. www.nccn.org/store/login/login. aspx?ReturnURL=http://www.nccn.org/ professionals/physician_gls/pdf/breast.pdf.

17. Senkus E., Kyriakides S., Penault F. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2013;24 Suppl 6:vi7–23.

18. Perez C.A., Graham M.L., Taylor M.E. Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 1994;74(1 Suppl):453–65.

19. Hortobagyi G.N., Ames F.C., Buzdar A.U. et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62(12):2507–16.

20. Hoang B., Reilly R.M., Allen C. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER-2-positive breast cancer cells. Biomacromolecules 2012;13(2):455–65.

21. Costantini D.L., Chan C., Cai Z. et al. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER-2/neu- amplified breast cancer. J Nucl Med 2007;48(8):1357–68.

22. Horton J.K., Halle J., Ferraro M. et al. Radiosensitization of сhemotherapy- refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 2010;76(4):998–1004.

23. Jacob J., Belin L., Gobillion A. et al. Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy. Cancer Radiother 2013;17(3):183–90.